Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis

Journal of Human Hypertension

Volumn 25, Issue 11, 2011, Pages 699-702

  Sandoo, A ^a,b   Panoulas, V F ^a   Toms, T E ^a   Smith, J P ^a   Stavropoulos Kalinoglou, A ^a   Metsios, G S ^a   Gasparyan, A Y ^a   Carroll, D ^b   Veldhuijzen Van Zanten, J J C S ^a,b   Kitas, G D ^a,c  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; GLYCERYL TRINITRATE; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MALE; MICROVASCULATURE; RHEUMATOID ARTHRITIS; SYSTOLIC BLOOD PRESSURE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; ENGLAND; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION MEDIATORS; LONGITUDINAL STUDIES; MICROVESSELS; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054070503     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2011.36     Document Type: Article

References (12)

1. Stamatelopoulos KS, Kitas GD, Papamichael CM, Chryssohoou E, Kyrkou K, Georgiopoulos G et al. Atherosclerosis in rheumatoid arthritis versus diabetes. A comparative study. Arterioscler Thromb Vasc Biol 2009; 29(10): 1702-1708.
2. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: State of the art and future perspectives. Ann Rheum Dis 2011; 70(1): 8-14.
3. Panoulas VF, Metsios GS, Pace AV, John H, Treharne GJ, Banks MJ et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47(9): 1286-1298.
4. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002; 2(5): 364-371. (Pubitemid 37328759)
5. Jacobsson LT, Turesson C, Gülfe A, Kapetanovic MC, Petersson IF, Saxne T et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32(7): 1213-1218. (Pubitemid 40995372)
6. Nadar S, Blann AD, Lip GY. Endothelial dysfunction: Methods of assessment and application to hypertension. Curr Pharm Des 2004; 10(29): 3591-3605. (Pubitemid 39386575)
7. Sandoo A, van Zanten JJ, Metsios GS, Carroll D, Kitas GD. The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J 2010; 4: 302-312.
8. Turner J, Belch JJ, Khan F. Current concepts in assessment of microvascular endothelial function using laser Doppler imaging and iontophoresis. Trends Cardiovasc Med 2008; 18(4): 109-116. (Pubitemid 351802262)
9. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA et al. Guidelines for the ultrasound assessment of endothelial-dependent flowmediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39(2): 257-265. (Pubitemid 34084631)
10. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2(8657): 244-247. (Pubitemid 19180612)
11. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti- TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163(3): 1521-1528. (Pubitemid 29352775)
12. Klarenbeek NB, van der Kooij SM, Huizinga TJ, Goekoop-Ruiterman YP, Hulsmans HM, van Krugten MV et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: A post hoc analysis from the BeSt trial. Ann Rheum Dis 2010; 69(7): 1342-1345.